A case of PML (progressive multifocal leukoencephalopathy) has been reported in a person who had been taking dimethyl fumarate (Tecfidera).
This new study found no long term association between any vaccines, including hepatitis B and HPV (human papillomavirus), and an increased risk of developing MS, for up to three years following vaccination.
Following the recent publication of the NICE Guideline for the management of MS in primary and secondary care (Clinical Guideline 186), NICE have now published their information for the public.
The Scottish Medicines Consortium (SMC), which issues guidance on whether treatments should be funded by NHS Scotland, has announced that fingolimod can now also be prescribed for people with rapidly evolving severe relapsing remitting MS (RES RRMS).
Today sees the publication of the first revision since 2003 of the NICE Guideline for the management of MS in primary and secondary care (Clinical Guideline 186).
The seasonal flu vaccination is now available to people who fall into at-risk groups, which includes anyone with a neurological condition such as multiple sclerosis, those over 65, and the main carers of a disabled person.